Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8152W HIGH $4.19
Volume
11.85 K
Value Traded
217.61 K
Short % Float
1.52%
-1.43%Week
-5.73%1 Month
-4.8%3 Month
-19.75%6 Month
-99.52%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.44 M
EPS (TTM)
-1.11
P/E Ratio
-
Ent. Value
-1.56 M
Total Shares
11.61 M
Float Shares
9.87 M
Insiders
15.07%
Institutions
5.57%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PHIO Catalyst Timeline
Dated clinical, regulatory and corporate events for Phio Pharmaceuticals Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Phio Pharmaceuticals Corp.
380Total events
3Upcoming
47Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPH-762Presentation
Phio management to meet investors and discuss PH-762 progress at H.C. Wainwright 28th Annual Global Investment Conference
cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinomasource ↗
●Type B MeetingPH-762FDA Meeting
FDA meeting request and briefing package submitted for PH-762 next-stage development
cutaneous squamous cell carcinomasource ↗
●Trial CompletionPH-762Trial
Formal completion of Phase 1b study of PH-762
cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinomasource ↗
●Pre NDA MeetingPH-762FDA Meeting
FDA meeting request and briefing package submitted for PH-762
cutaneous squamous cell carcinomasource ↗
▲Patent GrantedPH-894IP / Competition
U.S. Notice of Allowance for INTASYL composition targeting BRD4 with PH-894
▲Patent GrantedINTASYLIP / Competition
Multiple notices of allowance and grant decision for INTASYL compounds in US, Canada, Japan
◆Oral PresentationPresentation
Fireside chat with Force Family Office on Nobel Prize winning science takes on skin cancer
skin cancersource ↗
◆FDA Feedback ReceivedPH-762FDA Meeting
FDA engagement regarding next-stage clinical development targeted for Q2 2026
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
◆Oral PresentationPresentation
Phio Pharmaceuticals to present at Life Sciences Investor Forum
◆Oral PresentationPresentation
Phio Pharmaceuticals to present at H.C. Wainwright 27th Annual Global Investment Conference
▲Enrollment UpdatePH-762Trial
5th cohort patients now being treated in ongoing Phase 1b clinical trial
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
◆Enrollment UpdatePH-762Trial
5th cohort enrolling patients in ongoing Phase 1b trial
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
●Manufacturing MilestonePH-762CMC / Inspection
Entered into drug substance development services agreement with U.S. manufacturer
▲Manufacturing MilestonePH-762CMC / Inspection
Drug substance development services agreement with U.S. manufacturer for PH-762
cutaneous squamous cell carcinoma, Merkel cell carcinoma, melanomasource ↗
◆Enrollment UpdatePH-762Trial
Currently enrolling patients for 5th and expected final cohort in Phase 1b dose escalation study
cutaneous squamous cell carcinoma, Merkel cell carcinoma, melanomasource ↗
◆Enrollment CompletePH-762Trial
Anticipated completion of enrollment phase for Phase 1b trial of PH-762
cutaneous squamous carcinoma, Merkel cell carcinoma, melanomasource ↗
▲DSMB ReviewPH-762Trial
Safety Monitoring Committee recommended dose escalation to fifth cohort
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
▲Enrollment CompletePH-762Trial
Enrollment completed in fourth dose escalation cohort
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
▲Interim AnalysisPH-762Trial
Positive interim safety and efficacy results reported in Phase 1b trial of PH-762
skin cancersource ↗
◆Oral PresentationPH-762Presentation
Interim data presentation at ASCO 2025
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
◆Enrollment UpdatePH-762Trial
4th cohort currently enrolling and treating patients
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
◆PublicationRXI-231Presentation
Proof-of-concept data for RXI-231 published in Clinical, Cosmetic and Investigational Dermatology
hyperpigmentation disorderssource ↗
▲Full ResultsPH-762Clinical Data
Positive pathology results in third cohort: 2 of 3 cSCC patients with complete pathologic response
cutaneous squamous cell carcinomasource ↗
◆Oral PresentationPH-762Presentation
Podium presentation at SID 2025 on Phase 1b clinical trial results
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
▲DSMB ReviewPH-762Trial
Safety Monitoring Committee recommends dose escalation to fourth cohort
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
▲Enrollment MilestonePH-762Trial
Third cohort enrollment completed with 3 patients
cutaneous squamous cell carcinomasource ↗
◆Oral PresentationPH-762Presentation
Podium presentation at ITOC 11 on PH-762 and PH-894
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
▲Enrollment CompletePH-762Trial
Third dose cohort fully enrolled
cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinomasource ↗
▼Equity OfferingCorporate
Registered direct offering of 610,000 shares at $3.00 per share, with concurrent private placement of warrants
▼Equity OfferingCorporate
Registered direct offering of 1,063,670 shares at $3.00 per share, with concurrent private placement of warrants
Past FDA Catalysts and PDUFA Decisions
How PHIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | PH-762 | Phase 1b data presentation | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F18 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 96%
Micro Cap(rank 632 of 658)
Percentile Rank
Phio Pharmaceuticals Corp. has significant pipeline risk (18/100), with $24M risk-adjusted pipeline value, led by PH-762 in Squamous Cell Carcinoma of the Skin (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PH-762 Small moleculeCompletedNCT06014086 | Squamous Cell Carcinoma of the Skin | Phase 1 | COMPLETED | 22 | Mar 17, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every PHIO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PH-762 | cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma | Phase 1b | 2026-03-10 | In the Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, a pathological response rate of approximately 65% was observed across all dosing cohorts, with an 85% response rate (6 of 7 patients) in the highest-dose cohort.Read More | Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Plott Ronald ToddDirector | Buy | 5,000 42,000 held | $1.04 | 09/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PHIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PHIO for Q2 2026. | ||||
PHIO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PHIO ranks across every disease it competes in
Competitive Position is a premium feature
See how PHIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPHIO News
PHIO▼ -0.2%today
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
Phio Pharmaceuticals Corp. will present its INTASYL siRNA therapeutic platform at The Global Markets Virtual Forum on October 8, 2026. CEO Robert Bitterman will discuss the platform's potential to enhance immune-cell function in treating solid tumors. Investors can participate in real-time Q&A and schedule one-on-one meetings. The event aims to showcase Phio's innovative approach in cancer therapeutics.
Read more →PHIOPhio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
Phio Pharmaceuticals Corp. will present at the NIBA 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida. CEO Robert Bitterman will discuss the company's INTASYL siRNA gene-silencing platform and provide updates on their lead program, PH-762, aimed at treating cutaneous squamous cell carcinoma. The event offers a platform for in-depth discussions regarding Phio's strategic direction.
Read more →PHIOPhio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Phio Pharmaceuticals will present an update on its PH-762 program at the Life Sciences Future 2026 Conference. The presentation will cover the completed Phase 1b clinical study results in cutaneous squamous cell carcinoma and outline future development plans. CEO Robert Bitterman emphasized the potential of their INTASYL platform in addressing cancer treatment needs.
Read more →PHIOPhio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals has submitted a comprehensive briefing package to the FDA following the completion of its Phase 1b clinical study for PH-762, aimed at treating cutaneous squamous cell carcinoma. This submission marks a crucial step towards advancing the drug into Phase 2b clinical trials. The company is optimistic about the findings from the Phase 1b study and is preparing for the next stages of development.
Read more →PHIOPhio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Phio Pharmaceuticals announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026. Management will meet with investors to discuss the clinical candidate PH-762, which targets skin cancer. The conference provides an opportunity to highlight the company's strategic priorities and future development plans.
Read more →PHIOPhio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
Phio Pharmaceuticals has announced the receipt of a U.S. Notice of Allowance for its compound PH-894, which selectively targets the BRD4 protein. This development is significant for the company's INTASYL gene-silencing technology, which is aimed at treating proliferative and infectious diseases. The allowance marks a key milestone in their ongoing research and development efforts.
Read more →PHIOPhio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Phio Pharmaceuticals has reported significant advancements in its lead clinical candidate PH-762 during the second quarter of 2026. Key milestones include the initiation of commercial scale active pharmaceutical ingredient (API) production, completion of Phase 1b pharmacology studies, and announcements of new intellectual property. The company continues to progress in its development of therapeutics using its INTASYL® gene silencing technology.
Read more →PHIOCorrection to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Corp. announced its participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series. The event is scheduled for July 28, 2026, at 12 PM EDT. CEO Robert Bitterman will lead the presentation, highlighting the company's focus on its INTASYL® gene silencing technology aimed at cancer treatment.
Read more →PHIO▼ -6.2%on this newsshared move
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow on July 28, 2026. CEO Robert Bitterman will present the company's INTASYL siRNA platform and its lead candidate, PH-762, aimed at treating cutaneous carcinomas. The event will include a live Q&A session for investor engagement.
Read more →PHIOPhio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
Phio Pharmaceuticals has appointed Dr. R. Todd Plott to its Board of Directors. Dr. Plott brings a wealth of experience in patient care and dermatologic research, which may enhance the company's strategic direction. This move is expected to bolster Phio's efforts in developing therapeutics using its INTASYL® gene silencing technology.
Read more →PHIO▼ -13.6%on this news
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
Phio Pharmaceuticals has announced a significant patent milestone, securing additional protections for its INTASYL compounds in the United States, Canada, and Japan. This advancement is crucial for the company as it continues to develop its proprietary gene silencing technology aimed at eliminating cancer. The notices of allowance and grant decisions highlight the progress made in their clinical-stage biopharmaceutical efforts.
Read more →PHIO▼ -5.9%on this news
Phio Pharmaceuticals Announces “How siRNA Therapy can Change the Course of Cancer Treatment” in a Fireside Chat with Force Family Office on Monday, June 29, 2026
Phio Pharmaceuticals announced that CEO Robert Bitterman will participate in a fireside chat discussing siRNA therapy's potential in cancer treatment. The event, scheduled for June 29, 2026, will feature insights from Dr. Jim Cardia on the company's INTASYL® technology and its application in immuno-oncology. This highlights Phio's commitment to advancing cancer therapeutics.
Read more →PHIOPhio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
Phio Pharmaceuticals has announced the start of commercial-scale cGMP production of its lead candidate PH-762 at Nitto Denko Avecia. This milestone supports the upcoming clinical trial as the company progresses its intratumoral program. The recent completion of a Phase 1b dose-escalation study for PH-762 indicates promising developments in treating skin cancers.
Read more →PHIOPhio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
Phio Pharmaceuticals will participate in the Life Sciences Investor Forum on June 24-25, 2026. CEO Robert Bitterman will present the company's INTASYL siRNA platform, focusing on its lead candidate PH-762 for treating skin cancers. The event will feature a live Q&A session and one-on-one meetings for investors.
Read more →PHIOPhio Pharmaceuticals Announces “Innovations in Skin Cancer Treatment and Prevention” in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
Phio Pharmaceuticals will participate in a fireside chat on May 19, 2026, discussing innovations in skin cancer treatment. CEO Robert Bitterman and dermatologist Dr. Mary Spellman will highlight the company's INTASYL® gene silencing technology and its lead candidate PH-762, which is currently in a Phase 1b trial for skin cancers. The trial has reported positive pathological response rates.
Read more →PHIOPhio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Phio Pharmaceuticals reported its Q1 2026 financial results, highlighting the successful completion of its Phase 1b clinical trial for PH-762, aimed at treating skin cancer. The company secured key development agreements and strengthened its financial position with approximately $23.7 million in net proceeds from equity financings. While the trial data is pending formal analysis, an FDA submission is anticipated in Q2 2026 to discuss next steps for PH-762.
Read more →PHIOPhio Pharmaceuticals Announces “Nobel Prize Winning Science Takes on Skin Cancer” in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
Phio Pharmaceuticals is hosting a virtual fireside chat on April 15, 2026, featuring CEO Robert Bitterman and Dr. R. Todd Plott from Epiphany Dermatology. They will discuss the company's INTASYL technology and its lead candidate, PH-762, which targets skin cancer. The Phase 1b trial results indicate a significant pathological response rate, with FDA engagement planned for the second quarter of 2026.
Read more →PHIOPhio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
Phio Pharmaceuticals will present at the Centri Capital Conference on April 14, 2026. CEO Robert Bitterman will discuss the company's clinical advancements and the potential of its INTASYL technology in immuno-oncology. The event will take place at Nasdaq Marketsite in New York City, with a virtual attendance option available.
Read more →PHIOPhio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
Phio Pharmaceuticals has announced a cGMP manufacturing agreement for its lead compound, PH-762, aimed at treating cutaneous carcinomas. The agreement will support clinical trials and commercial supply. In a Phase 1b trial, PH-762 demonstrated a 65% pathological response rate in patients, with no reported serious adverse events. The company plans to engage with the FDA in the second quarter of 2026.
Read more →About Phio Pharmaceuticals Corp.
Headquarters411 SWEDELAND ROAD, KING OF PRUSSIA, PA, 19406
BIOPHARMAWATCH ELITE PLUS
Trade the next PHIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime